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6-Sulfo LacNAc, a Novel Carbohydrate Modification
of PSGL-1, Defines an Inflammatory Type
of Human Dendritic Cells
Initially, DCs were recognized in mouse spleen as cells
expressing MHC class II molecules and lacking lineage-
associated markers (Steinman, 1991). When these phe-
notypic criteria were applied to human blood leukocytes,
a small population of cells that lack CD3, CD14, CD16,
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DC2 are functionally distinguished by the pattern of cy-Aichi Cancer Center
tokine production, their capacity to polarize T cell reac-Nagoya, Japan
tions, migration behavior, and handling of pathogens4 Department of Immunology
(Rissoan et al., 1999; Siegal et al., 1999; Cella et al.,University of Go¨ttingen
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as classical sentinels in tissues lining the body surface
such as Langerhans cells in the epidermis (Ito et al.,
1999). DC1 as well as DC2 express CLA, which is knownSummary
to mediate binding to E selectin and homing to the skin
(Robert et al., 1999). DC2 are scarce in peripheral tissuesThe monoclonal antibody M-DC8 defines a major sub-
but relatively frequent in inflamed lymph nodes and ton-set of human blood dendritic cells (DCs). Here we iden-
sils. This tissue distribution might be facilitated by thetify the M-DC8 structure as 6-sulfo LacNAc, a novel
marked expression of L selectin (Cella et al., 1999),carbohydrate modification of the P selectin glycopro-
which is known to promote homing of naive T cells totein ligand 1 (PSGL-1). In contrast to previously de-
lymph nodes via high endothelial venules. In addition,scribed blood DCs, M-DC8 DCs lack the cutaneous
differential expression of chemokine receptors on imma-lymphocyte antigen (CLA) on PSGL-1 and fail to bind
ture and mature DCs critically governs the immigrationP and E selectin. Yet they express anaphylatoxin re-
of DC into peripheral tissues and their recruitment toceptors (C5aR and C3aR) and the Fc receptor III
draining lymph nodes (Banchereau et al., 2000). Re-(CD16), which recruit cells to inflammatory sites. While
cently, a third population of human blood DCs was iden-sharing with DC1 the expression of myeloid markers
tified with the help of the monoclonal antibody M-DC8and a potent capacity to prime T cells in vitro, M-DC8
(Scha¨kel et al., 1998). M-DC8 cells characteristicallyDCs produce far more TNF- in response to the bacte-
express the low-affinity receptor for IgG FcRIII andrial endotoxin lipopolysaccharide (LPS). Thus, 6-sulfo
have proved effective in a variety of in vitro T cell re-LacNAc-expressing DCs appear as a novel proinflam-
sponses.matory DC subset.
As we show here, M-DC8 cells account for the major-
ity of DCs in blood and exhibit a T cell stimulatory capac-Introduction
ity similar to that of DC1. However, M-DC8 cells lack
CLA, a carbohydrate modification located on PSGL-1
Dendritic cells (DCs) are pivotal regulators of immune
(Fuhlbrigge et al., 1997). M-DC8 cells, instead, express
responses. Depending on their maturation state they 6-sulfo LacNAc as a carbohydrate moiety on PSGL-1,
can promote or inhibit antigen-specific T cell activation. which is recognized by the mAb M-DC8 and two addi-
They collect antigen in the tissues and after further dif- tional mAbs (DD1 and DD2). Comparing the selectin
ferentiation present it to T lymphocytes in the lymphoid binding capacity of the different DC subpopulations,
organs. Among the various types of antigen-presenting it became apparent that CLA-expressing DCs but not
cells (APCs), DCs are characterized by their capacity to M-DC8 cells bind P and E selectin. Furthermore,
prime naive CD4 T helper cells and CD8 cytotoxic M-DC8 cells express receptors for the chemotaxins
T cells (Steinman, 1991; Banchereau et al., 2000). By C3a and C5a, which are known to mediate rapid recruit-
activating antigen-specific T cells, they constitute an ment of cells into areas of inflammation. M-DC8 cells
essential link between the innate and the adaptive de- migrate in response to C5a and upon stimulation with
fense systems. These “professional” APCs are exten- LPS produce the proinflammatory cytokine TNF- in
sively used for in vitro stimulation of T cells against large amounts, far more than is produced by monocytes
weakly immunogenic proteins or peptides. Furthermore, or DC1 under the same conditions.
they are increasingly employed to enhance the immune
response to tumor antigens in experimental vaccination Results
protocols (Fong and Engleman, 2000). On the other
hand, immature DCs can inhibit effector T cell function The mAb M-DC8 Recognizes 6-Sulfo LacNAc as a
in an antigen-specific manner (Dhodapkar et al., 2001). Novel Carbohydrate Modification of PSGL-1
In order to have a panel of mAbs available for the charac-
terization of the antigen defined by the mAb M-DC8, we5 Correspondence: rieber@rcs.urz.tu-dresden.de
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initially raised additional mAbs recognizing the same
cell population as mAb M-DC8. As immunogen we used
a Jurkat subline stably expressing the M-DC8-defined
epitope that we had produced by repetitive enrichment
of M-DC8 Jurkat cells. Two mAbs were obtained, mAb
DD1 and DD2, which showed the same cell staining
specificity as mAb M-DC8.
In Western blot analysis of membrane lysates pre-
pared from blood DCs, the mAb M-DC8 (Figure 1A, lane
1) as well as DD1 and DD2 (data not shown) identified
dispersed bands of 120 and 240 kDa. No such bands
were detected in lysates obtained from T cells and gran-
ulocytes (Figure 1A, lanes 3 and 4). Loss of the 240 kDa
band upon reduction (Figure 1A, lane 2) indicated that
the 120 kDa molecule is expressed as a disulfide-linked
dimer. The Western blot pattern resembled the results
obtained with the mAb KPL1, which recognizes PSGL-1
(Snapp et al., 1998) (Figure 1A, lanes 5 and 6). In contrast
to M-DC8, the KPL1 mAb reacted with lysates of blood
T cells as well as of granulocytes (Figure 1A, lanes 7
and 8).
To show that the M-DC8 mAb recognizes a determi-
nant on the PSGL-1 molecule, membrane lysates from
M-DC8 cells were immunoprecipitated by either the
M-DC8 or the KPL1 mAb followed by reduction, Western
blotting, and staining with both antibodies. The M-DC8
mAb revealed a band of the same size (120 kDa) on both
precipitates (Figure 1B, lanes 2 and 4) as did the KPL1
antibody (Figure 1B, lanes 6 and 8). These data provide
clear evidence that the M-DC8 determinant is a modifi-
cation of the PSGL-1 molecule occurring specifically in
a subset of circulating DCs.
To find out whether the M-DC8 modification also oc-
curs on other membrane molecules, CD43 was precipi-
tated from lysates of M-DC8 cells and checked for the
presence of M-DC8 determinants by Western blotting.
CD43 was chosen because of its mucin nature, its mo-
lecular size similar to that of monomeric PSGL-1, and its
differential decoration with certain carbohydrates (Fabbi
et al., 1999). As can be seen from Figure 1C, M-DC8-
defined epitopes were not found on CD43 molecules
precipitated by the mAb 6E5.
Hypothesizing that the M-DC8 epitope is a carbohy-
drate modification of PSGL-1, we asked whether the
M-DC8 epitope resides on an N- or O-linked carbohy-
drate moiety. For this biochemical analysis, we made
use of the Jurkat subline that was found to express the
M-DC8 epitope (Figure 2) as a modification of PSGL-1
like the M-DC8 cells (data not shown). Treatment of
Jurkat lysates with N-glycosidase F did not reduce the
intensity of staining with M-DC8 mAb in Western blot
analysis (data not shown), indicating that the epitope is
Figure 1. The mAb M-DC8 Recognizes a Specific PSGL-1-Depen-not part of an N-linked carbohydrate moiety. To examine
dent Epitopewhether the M-DC8 epitope resides on an O-linked carbo-
(A) Transmembrane proteins of M-DC8 DCs (lanes 1, 2, 5, and 6),hydrate structure, membrane lysates of M-DC8 Jurkat
granulocytes (lanes 3 and 7), and T cells (lanes 4 and 8) were sepa-cells were first treated with various cocktails of exogly-
rated by SDS-gel electrophoresis, blotted onto PVDF membranes,cosidases and neuraminidase together with O-glyca-
and probed with the mAbs M-DC8 or KPL1 (anti-PSGL1).
nase, which has a substrate specificity restricted to an (B) Proteins of M-DC8 DCs obtained by M-DC8, KPL1, or isotype-
unsubstituted disaccharide core (Glasgow et al., 1977). matched immunoprecipitation were reduced by 2-mercaptoethanol,
Since the binding site for the mAb M-DC8 was not re- and Western blots were stained as indicated.
(C) 6E5 (anti-CD43)-precipitated proteins of M-DC8 DCs weremoved by these treatments, we tried to block the gener-
probed for reactivity with the mAbs M-DC8 or 6E5.ation of O-linked carbohydrates by cultivating M-DC8
Jurkat cells for 7 days in the presence of benzyl-Gal-
NAc, a competitive inhibitor of O-glycosylation (Ulloa et
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Figure 2. O-Glycan- and 6-O-Sulfotransferase-Dependent but Sialic Acid-Independent Expression of M-DC8-Reactive Epitopes
The M-DC8 Jurkat subline was either cultured in the presence or absence of the competitive inhibitor of O-glycosylation benzyl-GalNAc
(A) or treated with neuraminidase to deplete sialic acid (B). Dot plots show results of flowcytometric analysis after double immunofluorescent
staining for PSGL-1 (clone KPL1) and M-DC8. (C) 6-O-sulfotransferase-transfected and mock-transfected ECV304 cells were stained with the
mAbs DD2, DD1, and M-DC8 and analyzed by flowcytometry. Filled histograms show mAb-staining, open histograms represent isotype
controls.
al., 2000). Expression of the M-DC8-epitope was mark- The failure to abrogate the M-DC8 reactivity by treat-
ment with a panel of exoglycosidases led us to investi-edly reduced by benzyl-GalNAc at a 0.25 mM concen-
tration and completely inhibited at 2.5 mM, while expres- gate whether a sulfate substitution served as a critical
component of the M-DC8 antigenic determinant. To thission of the PSGL-1 molecule remained unaffected
(Figure 2A). After removal of benzyl-GalNAc from the end, transfectants of the M-DC8 negative bladder carci-
noma cell line ECV304 were analyzed (Kimura et al.,culture, the Jurkat cells reexpressed the M-DC8 antigen.
The location of the M-DC8 epitope on O-glycans was 1999). 6-O-sulfotransferase-transfected but not mock-
transfected cells were stained by DD2, DD1, and M-DC8supported by the observation that treating membrane
lysates with O-sialoglycoprotease abolished M-DC8 re- (Figure 2C). The M-DC8 epitope was further character-
ized by testing the three mAbs by ELISA on an extendedactivity (data not shown). Treatment of the M-DC8 Jur-
kat subline with neuraminidase (Vibrio cholerae) did not panel of synthetic glycolipids differentially decorated
with sulfate, fucose, or sialic acid. The only structurereduce the staining intensity by M-DC8 mAb (Figure 2B),
which strongly suggests that the M-DC8 epitope does that was recognized by each of the DC-specific mAbs
was 6-sulfo LacNAc (Figure 3A). Whereas DD2 boundnot contain sialic acid.
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Figure 3. The mAbs M-DC8, DD1, and DD2 Specifically Recognize 6-Sulfo LacNAc
DC-specific mAbs DD2, DD1, and M-DC8 as well as the mAb AG107 were tested for their reactivity with differentially modified synthetic
glycolipids in an ELISA system (A). 6-sulfo LacNAc and 6,6-sulfo LacNAc were titrated (B) to confirm on a quantitative level that DD2 specifically
identifies 6-sulfo LacNAc.
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only to this structure, DD1 and M-DC8 also recognized magnetic cell sorting using the M-DC8 mAb. DC1 were
prepared at high purity by sequential depletion of lin-bi- and tri-sulfo LacNAc. Presence of sialic acid or fu-
cose on the LacNAc moiety abolished binding of all eage marker positive cells and of basophils being
C5aR, CD11cdim, HLA-DR–, which was followed bythree DC mAbs (Figure 3A). In contrast, mAb AG 107,
which has been raised against 6-sulfo Lewis X, recog- MACS isolation of DC1 based on their CD11c expres-
sion. As can be seen from Figure 5B, both DC popula-nized both fucosylated and non-fucosylated sulfo Lac-
NAc (Mitsuoka et al., 1998). The specificity of DD2 was tions efficiently stimulated proliferation of allogenic na-
ive CD4 cord blood T cells. When autologous T cellsconfirmed by testing mAb binding to serial dilutions of
6-sulfo LacNAc and, for comparison, to bi-sulfo LacNAc purified by negative depletion were stimulated by the
recall antigen tetanus toxoid (TT), DC1 proved to be(Figure 3B). These data indicate that 6-sulfo LacNAc is
the carbohydrate modification of PSGL-1 that is recog- superior in inducing a T cell proliferation in all donors
tested (Figure 5C). On the other hand, M-DC8 DCsnized by all three DC-specific mAbs.
were particularly potent in priming T cells against the
neoantigen KLH (Figure 5D). DC1 induced a marked6-Sulfo LacNAc Defines a Distinct Subset
autologous T cell response that was not observed withof Blood DC
M-DC8 DCs (Figures 6C and 6D).Previously defined blood DC subsets are characterized
as HLA-DR positive cells lacking lineage markers (CD3,
C5a Induces Migration of M-DC8 DCs In VivoCD14, CD16, CD19, and CD56) (O’Doherty et al., 1994).
Having shown that 6-sulfo LacNAc DCs but not DC1Based on the differential expression of CD11c and CD123,
and DC2 express receptors for C5a, we studied C5a-two major subpopulations, DC1 (CD11c CD123dim) and
induced cell migration in vivo. Purified M-DC8 DCsDC2 (CD11c– CD123high), have been delineated. Similarly
were injected intravenously into SCID mice that at theto DC1, M-DC8 cells showed a CD11c CD123dim phe-
same time received 10 g of C5a intraperitoneally. Fournotype (Figure 4A). The frequency of each of the three
hours later, peritoneal exudate cells were collected.blood DC populations was determined in PBMC prepa-
Staining with an HLA-DR-specific mAb revealed thatrations of twenty healthy adult donors according to the
4.5% to 7% of the injected cells could be recovered fromphenotypic characteristics as outlined in Figure 4A. For
the peritoneal cavity 4 hr after C5a challenge (Figure 6A),a clear distinction, the M-DC8 mAb was included in the
whereas DCs of human origin were not detected in thelineage mix. As shown in Figure 4B, cells displaying
peritoneal cavity of mice untreated with C5a (data not6-sulfo LacNAc comprised a major subset of blood DCs
shown). To prove that the peritoneal immigration of DCswhile the frequency of DC1 and DC2 was significantly
was dependent on C5a stimulation, M-DC8 DCs werelower.
preincubated with the C5aR-blocking mAb HC5aRZ1An extended analysis of M-DC8 DCs revealed a dis-
prior to injection. Under these conditions, no HLA-DRtinct phenotype that clearly differs from that of DC1 and
cells were found in the peritoneal cavity of C5a-chal-DC2 (Figure 4C). The most indicative marker of this subset
lenged mice (Figure 6A). As can be seen from Figure 6B,was the 6-sulfo LacNAc moiety on PSGL-1 defined by
almost all HLA-DR cells recovered from the peritonealthe mAbs M-DC8, DD1, and DD2. On the other hand,
cavity still carried the surface-bound M-DC8 mAb usedM-DC8 DCs lacked the PSGL-1 carbohydrate CLA,
for the immunomagnetic isolation of DCs from humanwhich was found at high density on all DC1 and DC2
blood.(Figure 4C). In addition, M-DC8 DCs failed to bind con-
structs of P and E selectin fused to human IgG, which
were avidly bound by DC1 and, to an even greater extent, M-DC8 DCs Exhibit a Marked Capacity
to Produce TNF-by DC2 in a strictly Ca2-dependent manner (Figure 4D).
The lack of selectin binding by M-DC8 cells is not due Functional C5aR are typically expressed by granulo-
cytes and monocytes that are involved in the first lineto interference by the M-DC8 mAb since experiments
in which PBMC were first incubated with P selectin-IgG of defense against pathogens (Werfel et al., 1992). Char-
acteristically, they secrete inflammatory cytokines uponfollowed by staining with M-DC8 mAb gave identical
results when compared with experiments where M-DC8 contact with pathogens. To see whether the C5aR-bear-
ing M-DC8 cells share with these cells the capacity tostaining preceded binding of selectins (data not shown).
In contrast to DC1 and DC2, M-DC8 DCs expressed produce this type of cytokines, we first stimulated PBMC
with LPS. After 4 hr, TNF- production by DC subsetsC5aR, C3aR, and CD16 but lacked L selectin (CD62L)
(Figure 4C). Similarly to DC2, M-DC8 DCs expressed and by monocytes was evaluated employing cytokine
staining of permeabilized cells. Greater than 90% of thehigh levels of CD45RA, low levels of CD45RO, and
lacked the expression of CD2. M-DC8 cells showed intracellular staining by an anti-
TNF- antibody, with a mean fluorescence intensity byM-DC8 cells and DC1 share the pattern of CD11c
and CD123 expression and presumably a myeloid origin far exceeding that of monocytes and DC1. Intact, nonper-
meabilized, Brefeldin A-treated cells were not stained,as suggested by the expression of CD33, CD13, and
CD11b. Therefore, it was of interest to compare their confirming the intracellular production of TNF- (Fig-
ure 7A).functional capacities as DCs. For this, the ability of
freshly isolated M-DC8 cells and DC1 to induce primary DC2 lacking CD14 and Toll-like receptor 4 (Kadowaki
et al., 2001) failed to produce TNF- upon LPS stimula-and secondary T cell immune responses in vitro was
assayed. The protocol for isolation of the two DC sub- tion. TNF- concentrations detected in the supernatants
of purified M-DC8 cells after 24 hr of LPS stimulationsets and the efficiency of purification is shown in Figure
5A. M-DC8 DCs were directly purified from PBMC by were approximately five times higher than those in su-
Immunity
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Figure 5. Capacity of M-DC8 Cells and DC1
to Activate T Cells against Different Antigens
M-DC8 cells and DC1 were purified as
shown by the flow sheet (A). Purity of the cell
preparations was tested by flowcytometry.
Graded numbers of purified M-DC8 cells
(circles) and DC1 (squares) were cocultured
with either allogeneic CD4 CD45RA cord
blood T cells (B) or autologous pan T cells
(open symbols) (C and D) in the presence of
TT (5 g/ml) (C) or KLH (10 g/ml) (closed
symbols) (D). After 5 days (B and C) or 7 days
(D), proliferation of T cells was determined by
[3 H] thymidine uptake. Values represent the
mean of triplicate samples. SEM was 15%.
The results shown are representative for five
(B and C) or six (D) independent experiments.
pernatants of identically treated purified monocytes dependent on the cell type, it undergoes differential
posttranslational modifications (Cummings, 1999). In(Figure 7B). When UV-inactivated herpes simplex virus
(HSV) was used for stimulation, M-DC8 DCs and mono- line with this view is our finding that the PSGL-1-specific
mAb KPL1 reacted with membrane lysates of M-DC8cytes produced only barely detectable TNF- (Figure
7C). In this study, DC2 that are known to secrete TNF- DCs as well as with lysates of T cells and granulocytes,
whereas the mAb M-DC8 only stained lysates of DCs inand IFN- in response to viral stimulation (Kadowaki et
al., 2000) were included as positive control. When puri- Western blot analysis. PSGL-1 has been shown to bind
P selectin, E selectin, and L selectin and to be involvedfied using the mAb BDCA-4 (Dzionek et al., 2000), DC2
were found to mount a significant TNF- secretion upon in the early steps of leukocyte diapedesis mediating
rolling and tethering of leukocytes along the endothe-HSV stimulation. This pattern of virus-induced TNF-
production also became apparent at the single cell level, lium (Cummings, 1999). The PSGL-1 polypeptide chain
itself, however, is not sufficient to mediate selectin bind-employing TNF- staining and gating for different DC
populations (data not shown). ing. For example, binding to P selectin requires core-2
branched O-glycosylation, 1,3 fucosylation, and 2,3
sialylation (Sako et al., 1993). One such sialylated, fuco-Discussion
sylated, and possibly also sulfated carbohydrate is
known as CLA (Mitsuoka et al., 1998). The mutually ex-In this study, the epitope recognized by the DC-specific
mAbs M-DC8, DD1, and DD2 was identified as 6-sulfo clusive staining of DC1 and DC2 on one hand and
M-DC8 cells on the other hand by the CLA-specificLacNAc, a unique, most probably O-linked carbohydrate
modification of PSGL-1. ELISA screening on a panel of mAb HECA-452 (Picker et al., 1990) and by the mAb
M-DC8 indicates that on circulating DCs PSGL-1 is mod-synthetic glycolipids revealed that the three DC-mAbs
differed in their fine specificities. Whereas mAb DD2 ified by either CLA or 6-sulfo LacNAc. CLA is known as
an E selectin ligand that is expressed by skin homing Treacted only with 6-sulfo LacNAc, mAb M-DC8 and DD1
additionally recognized the LacNAc backbone bearing cells (Picker et al., 1990) and by DCs rolling on dermal
endothelium (Robert et al., 1999). Both DC1 and DC2more than one sulfate residue. Since all three antibodies
labeled the same small population of blood leukocytes, bind E and P selectin (Robert et al., 1999), while ac-
cording to our results the majority of blood DCs expresswe conclude that the mono-sulfated LacNAc (6-sulfo
LacNAc) is selectively expressed as a modification of the non-sialylated, non-fucosylated, but sulfated carbo-
hydrate moiety that lacks E and P selectin binding activ-PSGL-1 on this DC subset. Furthermore, 6-sulfo LacNAc
appears to be the first cell type-specific carbohydrate ity. Our data do not definitely prove, yet provide strong
evidence, that the 6-sulfo LacNAc structure is locatedmodification of PSGL-1 being clearly resolved.
PSGL-1 is expressed on all blood leukocytes and, on an O-linked carbohydrate backbone. Whether the
Figure 4. Phenotype and Frequency of 6-Sulfo LacNAc DCs
DC1 and DC2 identified as HLA-DR cells lacking CD3, CD14, CD16, CD19, and CD56 (lineage markers) were assessed for CD11c and CD123
expression and compared with 6-sulfo LacNAc DCs as visualized by direct staining by the mAb M-DC8 (A). Applying the indicated gating
strategies (A) and including mAb M-DC8 in the lineage mix the frequency of DC subsets among PBMC was evaluated (n  20) (B). For statistical
analysis the student’s t test type 2 was used (* p  0,01). In (C) the phenotype of M-DC8 DCs is compared with CD11c DC1 and CD11c
DC2. The open histograms show the staining intensity obtained with the respective isotype control, the gray histograms give the staining
intensity obtained with mAb as indicated. In (D) the selectin binding capacity of the DCs is displayed. Herein binding of P and E selectin IgG
constructs in the presence (filled histogram) or absence of Ca2 (gray line) was evaluated and compared with the staining intensity of the
secondary antibody alone (dotted line).
Immunity
296
Figure 6. In Vivo Migration of M-DC8 Cells
in Response to C5a
SCID mice were injected into the peritoneal
cavity with human C5a (10 g) and intrave-
nously with M-DC8 DCs (1  107 ). After 4
hr, intraperitoneal cells were harvested and
stained for HLA-DR to identify migratory
M-DC8 DCs (A) (experiment one to five). In
additional experiments (six and seven),
M-DC8 DCs were incubated with 50 g of
a C5aR-blocking mAb (HC5aRZ1) prior to in-
travenous injection. Dot plots show represen-
tative results obtained by staining cells mi-
grated in response to C5a as in experiments
one through five for M-DC8 (IgM) still present
on the cell surface and for HLA-DR (B).
6-sulfo LacNAc structure interacts with a specific not al., 1999). M-DC8 DCs as well as DC1 have been re-
ported to be capable of inducing primary T cell immuneyet identified receptor on endothelial cells or whether it
serves a different function remains to be shown. responses in vitro (Scha¨kel et al., 1998; O’Doherty et al.,
1994). The stimulatory capacity of these DC populationsM-DC8 DCs turned out to be the most abundant
subset of blood DCs displaying a characteristic pheno- is evident right after their isolation from blood (Kohr-
gruber et al., 1999; Scha¨kel et al., 1998). Therefore, intype. M-DC8 cells but not DC1 or DC2 express mole-
cules known to mediate recruitment to inflammatory this study freshly prepared M-DC8 DCs and DC1 were
used for functional tests. Both DC populations revealedsites such as C5aR, C3aR, and CD16 (Coxon et al.,
2001). In addition, M-DC8 cells lacked expression of L a high capacity of inducing primary and secondary anti-
gen-specific T cell responses in vitro. As observed inselectin, which is employed by naive T cells and possibly
also by L selectin-expressing DC subsets such as DC1 all experiments, DC1 were better stimulators of T cells
against the recall antigen TT when compared withand DC2 to enter lymph nodes via high endothelial ven-
ules (Cella et al., 1999). Using an animal model, we show M-DC8 cells, while M-DC8 DCs appeared to be espe-
cially powerful in priming T cells specific for the neo-that C5aR-bearing M-DC8 cells migrate to the site of
C5a challenge, depending on functional C5aR. Accumu- antigen KLH. In contrast to M-DC8 DCs, DC1 caused
a distinct background proliferation of autologous T cellslation in inflamed tissues has also been reported for
CD16monocytes (Ha¨kkinen et al., 2000), another leuko- in the absence of TT or KLH. This autologous T cell
proliferation may be due to the procedure used to isolatecyte subset expressing CD16 at high density. These
cells were additionally found at increased frequency in the different cell subsets.
Inflammatory cells respond to LPS with a pronouncedthe blood of patients with septicemia (Fingerle et al.,
1993). CD16 monocytes differ from M-DC8 cells by TNF- secretion. The amount of TNF- produced by
M-DC8 DCs upon LPS stimulation by far exceeded thatthe expression of CD14, which was not detected on
M-DC8 cells (Figure 4C). A faint staining of a subset of DC1 and monocytes. M-DC8 DCs may thus have an
important function in the induction and amplification ofof M-DC8 cells might however be seen (Siedlar et al.,
2000) when using the CD14 mAb My4, which is sup- inflammatory reactions. TNF- produced in the pres-
ence of LPS may also equip M-DC8 cells with an addi-posed to identify a molecule different from CD14 (Ike-
moto et al., 1997). tional costimulatory potential in antigen-specific T cell
responses. Furthermore, M-DC8 cells were unable toM-DC8 DCs share with DC1 the high expression of
CD11c and the low expression of CD123 as well as respond to viral stimulation with TNF- (Figure 7) and
IFN- (H. Vallin, Uppsala, personal communication). Inantigens typical for myeloid cells (CD11b, CD13, and
CD33). Following maturation, DC1 become prominent this setting, DC2, which are known to mediate an anti-
viral immunity, appeared as principal producers ofinducers of Th1 cells via secretion of IL-12 (Rissoan et
6-Sulfo LacNAc Defines Inflammatory DC
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Figure 7. M-DC8 DCs Display a Unique
TNF--Producing Capacity after Stimulation
by LPS but Not by HSV
Dot plots were obtained by staining either
permeabilized or nonpermeabilized PBMC
after 4 hr of stimulation with LPS (100 ng/ml)
as indicated (A). Histograms display intracel-
lular TNF- staining of gated PBMC subsets
stimulated with LPS or left unstimulated.
Numbers of one representative experiment
out of five are given. The mean fluorescent
intensity (MFI) and the percentage of cells
staining positive for TNF- (filled) compared
to the respective isotype control (empty). 24
hr cell supernatants of purified cell popula-
tions were tested for secreted TNF- by
ELISA after stimulation with LPS (B) or HSV
(C). Depicted are the mean and SD of five
experiments in (B) and the mean of one out
of three experiments giving similar results (C).
TNF-, confirming previous findings (Kadowaki et al. cells as a distinct subset of circulating DCs with a proin-
flammatory capacity.2000) .
Taken together, we identified the mAb M-DC8 epitope
Experimental Proceduresas 6-sulfo LacNAc, an exclusive modification of PSGL-1
on the surface of the majority of human blood DCs. Their
Monoclonal Antibodiesstrong capacity to induce a primary antigen-dependent
Generation and staining specificity of mAb M-DC8 have been de-
T cell response in vitro, together with the expression of scribed previously (Scha¨kel et al., 1998). Two additional mAbs, DD1
receptors for anaphylatoxins and their striking capacity and DD2, both of IgM isotype, recognizing the same small leukocyte
population in human blood as the M-DC8 mAb, were obtained byto produce TNF- upon LPS stimulation, define M-DC8
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immunizing mice with a subline of Jurkat cells selected for stable Western Blot Analysis and Immunoprecipitation
Protein lysates were incubated at 95	C for 5 min in sample bufferexpression of the M-DC8 epitope, fusion of mouse spleen cells
with the myeloma cell line Px63-Ag8.653, and screening hybridoma containing 5% SDS and 2 M urea. For enhanced reduction, samples
were additionally treated with 2-mercaptoethanol overnight at 37	C.supernatants by FACS analysis for staining of human blood leuko-
cytes. The mAb HC5aRZ1 and HC3aRZ1 were generated in the Depending on the mAb to be applied for immunoblotting, either 30
g (mAb M-DC8 and 6E5) or 2 g (mAb DD2 and KPL1) of proteinlaboratory of one of the authors (J.Z.) by immunizing mice with RBL-
2H3 cells transfected with human C5aR and C3aR, respectively was loaded on 5.7% polyacrylamide minigels using acrylamide:bisa-
crylamide at a ratio of 37.5:1 (Roth, Karlsruhe, Germany). Gels were(Zwirner et al., 1999). Supernatants of hybridomas generated ac-
cording to standard techniques were tested for their reactivity with blotted onto PVDF membranes (Pall, Portsmouth, UK), blocked with
1% blocking reagent (Roche, Mannheim, Germany), and probed forpeptides representing the N-terminal 31 amino acids of the C5aR
and with RBL-2H3 transfectants, respectively. In additional experi- 1 hr with 1:20 diluted hybridoma supernatant of the mAbs M-DC8
and DD2, or anti-PSGL-1 (clone KPL1, 2 g/ml) and anti-CD43 (6E5ments, the mAb HC5aRZ1 was shown to block binding of fluores-
cein-conjugated recombinant C5a to its receptor on RBL-2H3 ascites diluted 1:100). Bound antibody was visualized with goat anti-
mouse Ig coupled to alkaline phosphatase (Biosource, Ratingen,transfectants. CD43 mAb 6E5 was kindly provided by Dr. O. Majdic,
University of Vienna, Austria. mAb AG107 was raised in the labora- Germany) and NBT/BCIP.
For immunoprecipitation, 30 g of integral membrane proteinstory of one of the authors (R.K.) against 6-sulfo Lewis X. It recognizes
both fucosylated and non-fucosylated sulfo LacNAc (Mitsuoka et was either incubated for 2 hr with M-DC8 mAb absorbed onto protein
A-Sepharose by means of rabbit anti-mouse IgM (Dianova, Ham-al., 1998). The CD8 mAb M-T811 (IgG) (Rieber et al. 1981) and the
CD14 mAb M-M42 (IgM) (Wilhelm et al. 1986) originate from the burg, Germany) or with 20 g of anti-PSGL-1 (mAb KPL1) followed
by overnight incubation with protein G-Sepharose. For precipitationlaboratory of one of the authors (E.P.R.). Other mAb (mAb clones)
were obtained from commercial sources: IgG1 isotype-control of CD43, lysates were incubated with 10 l of anti-CD43 mAb 6E5
containing ascites followed by protein G-Sepharose. IgG1 (CD8,(107.3), IgG1 isotype-control (MOPC-21) Fitc/Pe, IgG2b isotype-
control (27-35) Fitc/Pe, anti-HLA-DR (G46-6) CyChrome, anti-HLA- M-T811) and IgM (CD14, M-M42) isotype-matched control antibod-
ies were used in parallel. All immunoprecipitates were washed threeA,B,C (G46-2.6) Fitc, anti-CD1a (HI149) Pe, anti-CD2 (RPA-2.10) Pe,
anti-CD3 (HIT3a) Pe, anti-CD11c (S-HCL-3) APC, anti-CD13 (WM15) times with lysis buffer containing 0.1% Nonidet P40, extracted for
electrophoresis with SDS- and 2-mercaptoethanol-containing sam-Pe, anti-CD14 (M5E2) Pe, anti-CD16 (3G8) Pe, anti-CD19 (HIB19)
Pe, anti-CD32 (FLI8.19(2003)) Fitc, anti-CD33 (WM53) Pe, anti-CD40 ple buffer at 95	C for 5 min and 37	C overnight, followed by PAGE
and immunoblotting as described above.(HI30) Fitc, anti-CD45RA (HI100) Pe, anti-CD54 (B159) Pe, anti-CD56
(MY31) Pe, anti-CD61 (DRE56), anti-CD80 (L307.4) Pe, anti-CD86
(2331(FUN-1)) Fitc, anti-CD123 (7G3) Pe, anti-PSGL-1 (KPL1), and Blocking O-Glycosylation and Treatment with Sialidase
The M-DC8 Jurkat subline generated as described in the Resultsanti-CLA (HECA-452) Fitc were all obtained from Becton Dickinson
Pharmingen, Heidelberg, Germany; anti-CD4 (MT310) Pe, anti- section was maintained in RPMI 1640 medium supplemented with
2 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential aminoCD11b (ZLPM19c) Pe, and anti-CD45RO (IOL3) Pe were purchased
from DAKO, Hamburg, Germany; anti-CD64 (22) Fitc, anti-CD58 acids, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% heat
inactivated fetal calf serum (all from Biochrom AG, Berlin, Germany).(AICD58) Pe, and IgG2a isotype-control (U7.27) Pe from Beckman
Coulter, Unterschlei
heim, Germany; anti-CD1c (BDCA-1) Fitc and O-glycosylation was inhibited by culturing M-DC8 Jurkat cells with
0.25 and 2.5 mM benzyl-GalNAc (in methanol, stock 250 mM,anti-BDCA-4 Pe were kindly provided by Miltenyi, Bergisch Glad-
bach, Germany, and IgG2a isotype-control (GMG1A01) Fitc was Sigma, Deisenhofen, Germany) and by adding fresh benzyl-GalNAc
when cells were split on day 3 and 6. On day 7, cells were eitherobtained from Cedar Lane, Hornby, Ontario, Canada.
used for FACS analysis or washed two times and cultured for an
additional 7 days without benzyl-GalNAc. Cells cultured in thePreparation of Cell Lysates
presence of the solvent alone in the respective concentrationsHeparinized blood and buffy coat preparations were obtained from
served as controls. Double immunofluorescence staining was donethe Department of Blood Transfusion, Medical Faculty, TU Dresden,
for PSGL-1 (clone KPL1) followed by Pe-conjugated mouse IgG-with the informed consent of the blood donors. PBMC were pre-
specific goat F(ab)2 and M-DC8 followed by Fitc-conjugated mousepared by Ficoll-Hypaque (Pharmacia, Freiburg, Germany) density
IgM-specific goat F(ab)2 (both Beckman Coulter). For sialidasecentrifugation. M-DC8 cells were isolated as previously described
treatment, 1  107 M-DC8 Jurkat cells were incubated in 1 ml PBS(Scha¨kel et al.,1998). In brief, PBMC were incubated with 1:20 diluted
(pH 6.5) at 37	C for 30 min with 0.1 unit/ml sialidase (Vibrio cholerae,M-DC8 hybridoma supernatant, followed by incubation with rat anti-
Roche, Mannheim, Germany).mouse IgM microbeads (Miltenyi). Cells were resuspended in ice-
cold degassed running and elution buffer (PBS, 1% FCS) containing
Antibody Binding to Sulfated Carbohydrate Determinants2 mM EDTA to avoid clumping of cells. M-DC8 cells were selected
Differentially modified synthetic glycolipids synthesized as de-by magnetic cell sorting using an LS column; to obtain a purity
scribed previously (Brandley et al., 1993; Kameyama et al., 1991;of 96%, cells were subjected to a second round of cell sorting.
Komba et al., 1996) were immobilized at the bottom of 96-well platesFor Western blotting, T lymphocytes were isolated by rosetting with
for ELISA using a standard method (Mitsuoka et al., 1998). BindingAET-treated sheep red blood cells as previously described (Scha¨kel
of antibodies was probed using peroxidase-conjugated goat anti-et al., 1998). Granulocytes were obtained after hypotonic lysis of
mouse IgM (-chain-specific; Cappel Inc., Malvern, PA). mAb AG107red blood cells from pellets after Ficoll-Hypaque density gradient
recognizing both 6-sulfo LacNAc and 6-sulfo Lewis X was describedcentrifugation.
previously (Uchimura et al., 1998).Integral plasma membrane proteins were prepared by differential
pelleting of homogenized cells followed by Na2CO3 extraction as
Cellular Transfection of 6-O-Sulfotransferasedescribed by Pasquali et al. (1997). In brief, 1 108 purified M-DC8
The human bladder carcinoma cell line ECV304 was either trans-cells, T lymphocytes, or granulocytes pooled from different donors
fected with mock plasmids or 6-O-sulfotransferase as previouslywere resuspended in hypotonic buffer (42 mM KCl, 5 mM MgCl2, 5
described (Kimura et al., 1999). In brief, ECV304 maintained in DMEMmM iodoacetamide, 10 mM Hepes [pH 7.4] supplemented with 1
and 5% FCS were transfected by electroporation with pIRES1hyg-g/ml aprotinin, 1 g/ml leupeptin, and 100 g/ml PMSF) and ho-
6-Sul-T using an ECM600 Electro-Cell Manipulator (BTX, San Diego,mogenized using a dounce homogenizer. Cell nuclei were pelleted
USA). This was followed by selection of transfected cells by culturingby centrifugation at 500  g and supernatants were transferred into
in medium containing hygromycin. Cells grown in selecting mediuma new tube to pellet plasma membranes at 20,000 g. Supernatants
were used as the 6-O-sulfotransferase transfectant cells for furtherwere discarded and the pellets were extracted twice with 2 ml of
experiments without any cloning procedure.0.1 M Na2CO3 (pH 11.0), followed by centrifugation at 100,000  g
to detach nonintegral membrane proteins. The pellets were lysed
in buffer containing 1% Nonidet P-40, 150 mM NaCl, 150 mM Na- Cell Surface Staining
For flowcytometric analysis, 1  106 ECV304 cells or PBMC wereborate (pH 8), and protease inhibitors (as above), and clarified by
centrifugation at 12,000  g. incubated with 1:20 M-DC8 hybridoma and Fitc/Pe/CyChrome-con-
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jugated mAbs followed by Fitc-/Pe-conjugated mouse IgM-specific C5a-Induced Migration of M-DC8 Cells
1  107 purified M-DC8 DCs isolated by MACS were resuspendedgoat F(ab)2. For phenotyping of DC1 and DC2, PBMC were incu-
bated with a cocktail of Fitc/Pe-conjugated lineage-associated in 200 l PBS and injected into the tail vein of SCID mice (weight
19 to 23 g) (Charles River, Sulzfeld, Germany). In parallel, 200 lmAbs (anti-CD3, -CD14, -CD16, -CD19, -CD56), HLA-DR-CyChrome,
and Fitc/Pe-conjugated mAbs as indicated. Gating for DCs was PBS containing 10 g of recombinant human C5a (Rothermel et al.,
1997) was injected intraperitoneally. After 4 hr, mice were sacrificeddone as shown in Figure 4A. When unconjugated mAbs were used,
PBMC were first incubated with purified mAb (all mouse IgG) fol- and cells were harvested from the peritoneum by flushing with 10
ml of PBS. Obtained cells were counted and stained using isotypelowed by Pe-conjugated mouse IgG-specific goat F(ab)2. Free bind-
ing was blocked with 10% mouse serum, followed by staining with controls (IgG2a) or anti-HLA-DR-Pe (all from Becton Dickinson/
Pharmingen) and with Fitc-conjugated mouse IgM-specific goatFitc/Pe/CyChrome-conjugated mAbs as above. Flow cytometric
analysis was performed on a FACScan and FACScalibur cytometer F(ab)2, thereby identifying cells of human origin and M-DC8 mAb
remaining on the cell surface after MACS isolation.(Becton Dickinson).
TNF- Production
Selectin Binding For intracytoplasmic cytokine staining, PBMC prepared from hepa-
To evaluate binding of selectins, the method previously described rinized blood of normal donors were stimulated with 100 ng/ml LPS
by Marquardt et al. (1999) was adopted. In brief, 1  106 PBMC (Escherichia coli 026:B6; Sigma) supplemented with 1 g/ml Brefel-
were stained with fluorescent mAbs for the identification of M-DC8 din A (Sigma). After 4 hr at 37	C and 5% CO2, cells were harvested,
DCs, DC1 and DC2 as described above, and then resuspended in stained for cell surface markers as indicated, fixed with freshly pre-
Hank’s balanced salt solution containing 1% FCS, 0.04% azide, and pared ice-cold 4% paraformaldehyde for 15 min, and permeabilized
Fc-receptor-blocking antibodies (30 g/ml anti-CD32, IV.3, Serotec, using 0.1% Saponin in PBS. Subsequently, cells were stained for
Oxford, UK; 30 g/ml anti-CD16, 3G8, Becton Dickinson/Phar- TNF- production for 15 min (using Pe-coupled MAb11, Becton
mingen). This was followed by a 12 min incubation with 25 g/ Dickinson/Pharmingen) and washed twice with 0.1% Saponin in
ml of either P selectin-hum-IgG or E selectin-hum-IgG (both R&D, PBS before flowcytometric analysis.
Wiesbaden, Germany) at 4	C. Cell surface-bound selectins were For analysis of secreted TNF-, purified monocytes isolated by
visualized by Pe-labeled F(ab)2 donkey anti-human-IgG (5 g/ml, negative selection or positive enrichment (Miltenyi), DC2 purified by
Dianova) and flowcytometric analysis. Binding specificity was con- MACS using the mAb BDCA-4 and M-DC8 DCs were cultured for
trolled by incubating a second sample in Hank´s balanced salt solu- 24 hr at a density of 1  106 /ml. Stimulation was done using 100
tion lacking Ca2 and containing EDTA at a concentration of 5 ng/ml LPS or UV-inactivated (1 J at 254 nm) HSV at a concentration
mmol/l. of 2 107 PFU/ml (kind gift of Dr. Gunnar Alm, Swedish University
of Agricultural Sciences Veterinary Immunology, Uppsala, Sweden).
The respective HSV lot had previously been tested for its capacity
Cell Preparation for T Cell Proliferation Assays to induce a vigorous IFN- production by DC2 (Vallin et al., 1999).
Sodium citrate-treated blood (450 ml) was subjected to Ficoll hy- Secreted TNF- was measured in the supernatants using an ELISA
paque gradient centrifugation yielding 0.7–1.4  109 PBMC from kit (Becton Dickinson/Pharmingen) according to the manufacturer’s
which 1  108 PBMC were set aside for isolation of T cells. The instructions.
remaining cells were first subjected to MACS purification of M-DC8
cells as described above with the exception that the running buffer
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